These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33190819)

  • 1. [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
    Bottemanne H; Claret A; Fossati P
    Encephale; 2021 Apr; 47(2):171-178. PubMed ID: 33190819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
    Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; Rosenblat JD; Castle D; McIntyre RS
    CNS Drugs; 2022 Jan; 36(1):17-30. PubMed ID: 34791625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
    Olivier B; Olivier JDA
    Adv Exp Med Biol; 2024; 1456():49-66. PubMed ID: 39261423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
    Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
    Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
    Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
    Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways.
    Ren L
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
    Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
    ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation antidepressants with novel mechanisms for treatment resistant depression.
    Chen MH; Tu PC; Su TP
    Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible place for psychedelics in pharmacotherapy of mental disorders.
    Wojtas A
    Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New investigational agents for the treatment of major depressive disorder.
    Pochwat B; Krupa AJ; Siwek M; Szewczyk B
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
    Johnston JN; Kadriu B; Allen J; Gilbert JR; Henter ID; Zarate CA
    Neuropharmacology; 2023 Mar; 226():109422. PubMed ID: 36646310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.
    Wong S; Kwan ATH; Teopiz KM; Le GH; Meshkat S; Ho R; d'Andrea G; Cao B; Di Vincenzo JD; Rosenblat JD; McIntyre RS
    J Affect Disord; 2024 Apr; 350():698-705. PubMed ID: 38244804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
    Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
    Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rapid-acting antidepressants-neurobiological mechanisms of action].
    Gass P; Vasilescu AN; Inta D
    Nervenarzt; 2022 Mar; 93(3):223-233. PubMed ID: 34766186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
    Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
    J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychedelic and dissociative agents in psychiatry: challenges in the treatment].
    Jungwirth J; Bavato F; Quednow BB
    Nervenarzt; 2024 Sep; 95(9):803-810. PubMed ID: 39196383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.